MarginsXMarginsX
Home › Markets › Health Care › RGNX

REGENXBIO Inc. (RGNX)

RGNX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.32
-4.19% on the day
Market cap
$484.0M
Small cap
Revenue · 2025
$170.4M
+104.5% on 2024
Net income · 2025
-$193.9M
-113.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/0001193125-26-094013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRGNX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2015
SEC CIK0001590877
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$170.4M
Net income-$193.9M
Operating income-$161.2M
Net margin-113.8%
Operating margin-94.6%
Revenue growth+104.5%
Cash$34.5M
Total assets$453.0M
P/E (computed)Net income was not positive
P/S (computed)2.8×

Warning signs

Cash runway
7.6 months
$95.8M cash at September 30, 2026
Share count, 1 year
+30.6%
2025-10-31 to 2026-10-30 · +50.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
-$253K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued."
10-Q 2026-11-05
Cash and burn$95.8M cash; operating cash flow -$38.0M a quarter.Report 2026-09-30
Shares outstanding66,122,600 (2026-10-30); 50,623,086 a year earlier; 43,991,980 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-07-17
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Washington, District of Columbia, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $950K, sold $1.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$9.2M-$40.7M$38.6M$95.8MNo debt tags$153.9M10-Q 2026-11-05
Q2 2026
2026-06-30
$108.0M$22.7M-$62.2M$36.5MNo debt tags$174.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$6.4M-$90.1M-$76.2M$15.2MNo debt tags$87.8M10-Q 2026-05-14
Q4 2025
2025-12-31
$30.3M-$67.1M-$52.3M$34.5MNo debt tags$170.4M10-K 2026-03-05
Q3 2025
2025-09-30
$29.7M-$61.9M-$56.0M$58.8MNo debt tags$161.3M10-Q 2026-11-05
Q2 2025
2025-06-30
$21.4M-$70.9M-$49.3M$79.6MNo debt tags$155.8M10-Q 2026-08-06
Q1 2025
2025-03-31
$89.0M$6.1M$33.6M$130.1MNo debt tags$156.7M10-Q 2026-05-14
Q4 2024
2024-12-31
$21.2M-$51.2M-$31.6M$57.5MNo debt tags$83.3M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-17
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-14

Source: SEC EDGAR submissions feed, 806 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.3%
1 month+5.2%
3 months-28.3%
Year to date-46.9%
1 year-34.4%
From 52-week high-52.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CADLCandel Therapeutics Inc.$5.81-6.29%$455.8M
FENCFennec Pharmaceuticals Inc.$12.76+9.81%$450.5M
ETRAElectra Therapeutics Inc.$8.31-6.00%$522.4M
ENTXEntera Bio Ltd.$3.02-2.89%$525.9M
VALNValneva SE$5.65-0.18%$536.1M
DNAGinkgo Bioworks Holdings Inc.$8.50-11.55%$551.0M
TVGNTevogen Inc.$6.22+3.67%$422.2M
TECXTectonic Therapeutic Inc.$20.98-0.76%$418.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier